Single-dose liposomal amphotericin B (AmBisome®) for the treatment of Visceral Leishmaniasis in East Africa: study protocol for a randomized controlled trial
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1745-6215
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Single-dose liposomal amphotericin B (AmBisome®) for the treatment of Visceral Leishmaniasis in East Africa: study protocol for a randomized controlled trial ; volume:12 ; number:1 ; day:6 ; month:3 ; year:2011 ; pages:1-7 ; date:12.2011
Trials ; 12, Heft 1 (6.3.2011), 1-7, 12.2011
- Urheber
-
Edwards, Tansy
- Beteiligte Personen und Organisationen
-
Omollo, Raymond
Khalil, Eltahir AG
Yifru, Sisay
Musa, Brima
Musa, Ahmed
Wasunna, Monique
Smith, Peter G.
Royce, Catherine
Ellis, Sally
Balasegaram, Manica
Hailu, Asrat
SpringerLink (Online service)
- DOI
-
10.1186/1745-6215-12-66
- URN
-
urn:nbn:de:1111-2016050220534
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:53 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Edwards, Tansy
- Omollo, Raymond
- Khalil, Eltahir AG
- Yifru, Sisay
- Musa, Brima
- Musa, Ahmed
- Wasunna, Monique
- Smith, Peter G.
- Royce, Catherine
- Ellis, Sally
- Balasegaram, Manica
- Hailu, Asrat
- SpringerLink (Online service)
Ähnliche Objekte (12)
Feasibility, acceptance and safety of treating visceral leishmaniasis patients with liposomal amphotericin B in rural Bangladesh
Safety and efficacy of liposomal amphotericin B for treatment of complicated visceral leishmaniasis in patients without HIV, North-West Ethiopia
Therapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOME™10, a new liposomal amphotericin B
A severe case of visceral leishmaniasis and liposomal amphotericin B treatment failure in an immunosuppressed patient 15 years after exposure
Amphotericin B deoxycholate for relapse visceral leishmaniasis in Bangladesh: a cross-sectional study
Visceral leishmaniasis complicated with hemophagocytic lymphohistiocytosis and resistant to amphotericin B: a case report
Mediastinal Lymphadenopathy in Visceral Leishmaniasis
Relationship of serum antileishmanial antibody with development of visceral leishmaniasis, post-kala-azar dermal leishmaniasis and visceral leishmaniasis relapse
Pediatric visceral leishmaniasis in Tartous, Syria
Comorbid infections induce progression of visceral leishmaniasis
Spontaneous remission of fully symptomatic visceral leishmaniasis
Safety and Efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial
Feasibility, acceptance and safety of treating visceral leishmaniasis patients with liposomal amphotericin B in rural Bangladesh
Safety and efficacy of liposomal amphotericin B for treatment of complicated visceral leishmaniasis in patients without HIV, North-West Ethiopia
Therapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOME™10, a new liposomal amphotericin B
A severe case of visceral leishmaniasis and liposomal amphotericin B treatment failure in an immunosuppressed patient 15 years after exposure
Amphotericin B deoxycholate for relapse visceral leishmaniasis in Bangladesh: a cross-sectional study
Visceral leishmaniasis complicated with hemophagocytic lymphohistiocytosis and resistant to amphotericin B: a case report
Mediastinal Lymphadenopathy in Visceral Leishmaniasis
Relationship of serum antileishmanial antibody with development of visceral leishmaniasis, post-kala-azar dermal leishmaniasis and visceral leishmaniasis relapse
Pediatric visceral leishmaniasis in Tartous, Syria
Comorbid infections induce progression of visceral leishmaniasis
Spontaneous remission of fully symptomatic visceral leishmaniasis
Safety and Efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial
Feasibility, acceptance and safety of treating visceral leishmaniasis patients with liposomal amphotericin B in rural Bangladesh
Safety and efficacy of liposomal amphotericin B for treatment of complicated visceral leishmaniasis in patients without HIV, North-West Ethiopia
Therapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOME™10, a new liposomal amphotericin B
A severe case of visceral leishmaniasis and liposomal amphotericin B treatment failure in an immunosuppressed patient 15 years after exposure
Amphotericin B deoxycholate for relapse visceral leishmaniasis in Bangladesh: a cross-sectional study
Visceral leishmaniasis complicated with hemophagocytic lymphohistiocytosis and resistant to amphotericin B: a case report
Mediastinal Lymphadenopathy in Visceral Leishmaniasis
Relationship of serum antileishmanial antibody with development of visceral leishmaniasis, post-kala-azar dermal leishmaniasis and visceral leishmaniasis relapse
Pediatric visceral leishmaniasis in Tartous, Syria
Comorbid infections induce progression of visceral leishmaniasis
Spontaneous remission of fully symptomatic visceral leishmaniasis